POZEN Logo
Print Page   Close Window

Press Release

POZEN to Present at the Susquehanna Financial Group's Second Annual Significant Options in Healthcare Conference

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 14, 2008--POZEN Inc. (NASDAQ:POZN) announced today that John R. Plachetka Pharm.D., the company's chairman, president and chief executive officer, will present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference on Tuesday, March 4, 2008 at 12:30 p.m. (ET) at the W Hotel in New York.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Treximet(TM) which is currently under review by the United States Food and Drug Administration for the acute treatment of migraine, and with AstraZeneca for the proposed product candidate PN 400 for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

CONTACT: POZEN Inc.
Bill Hodges, Chief Financial Officer, 919-913-1030;
Fran Barsky, Director, Investor Relations, 919-913-1044

SOURCE: POZEN Inc.